PMID: 3651840Jul 1, 1987Paper

N,N-dipropargyl-2-phenylethylamine, a potential prodrug of 2-phenylethylamine: neurochemical and neuropharmacological studies in rat

Brain Research Bulletin
T S RaoR T Coutts

Abstract

An evaluation of N,N-dipropargyl-2-phenylethylamine (DPGPEA) as a prodrug to increase brain levels of 2-phenylethylamine (PEA) was conducted in rats. A 0.1 mmol/kg (IP) dose of DPGPEA was administered and produced marked elevations of PEA levels in brain, liver and blood which were sustained for several hours. Ex vivo MAO inhibition data indicated DPGPEA to be an inhibitor of MAO-B, although the effect was much weaker than seen with tranylcypromine or pargyline. DPGPEA caused brain noradrenaline, dopamine and 3,4-dihydroxyphenylacetic acid levels to temporarily decrease significantly below controls. Concomitant increases in homovanillic acid and 5-hydroxyindole-3-acetic acid levels suggest that the PEA or N-propargylPEA formed and/or DPGPEA itself have significant effects on release and reuptake of neurotransmitters. DPGPEA was also shown to be metabolized to N-propargyl-PEA, another prodrug of PEA, in vivo.

References

May 1, 1976·The Journal of Pharmacy and Pharmacology·G B BakerR del Carmine
Apr 2, 1979·Clinica Chimica Acta; International Journal of Clinical Chemistry·M SandlerA Coppen
Jun 1, 1979·British Journal of Clinical Pharmacology·R PirisinoC Curradi
Jul 1, 1979·Journal of Neurochemistry·S R Philips, A A Boulton
Dec 1, 1978·British Journal of Clinical Pharmacology·G P ReynoldsG M Stern
Jan 14, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·P C WaldmeierL Maître
Jan 1, 1975·Canadian Journal of Biochemistry·P H Wu, A A Boulton
Nov 15, 1975·Biochemical Pharmacology·T J MantleR F Long
Feb 1, 1986·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·T YoshidaY Kuroiwa
Jul 1, 1987·Naunyn-Schmiedeberg's Archives of Pharmacology·T S RaoR T Coutts
Mar 1, 1986·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A M Weli, B Lindeke
Jun 1, 1986·Canadian Journal of Physiology and Pharmacology·R T CouttsF M Pasutto
Jun 1, 1985·Biochemical Pharmacology·A M Weli, B Lindeke
May 13, 1985·Life Sciences·P A LundbergG Engberg
Aug 1, 1971·The Journal of Pharmacy and Pharmacology·D M Jackson
Feb 1, 1974·Biochemical Pharmacology·C H Williams, J Lawson
May 6, 1971·Journal of Chromatography·A A Boulton, L Milward
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·A A Boulton
Nov 1, 1980·Neuropharmacology·R S SloviterE G Drust
Jan 1, 1984·Progress in Neuro-psychopharmacology & Biological Psychiatry·R A LocockW G Dewhurst
Nov 9, 1981·Life Sciences·R T CouttsF M Pasutto
Jan 1, 1981·Progress in Neuro-psychopharmacology·G B Baker, D L Yasensky
Dec 1, 1963·Biochemical Pharmacology·R J WURTMAN, J AXELROD

❮ Previous
Next ❯

Citations

Jan 1, 1989·General Pharmacology·A D MosnaimM E Wolf
Jan 7, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·G ZhouT Matsuishi
May 9, 2008·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ana L SimplícioJohn F Gilmer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.